Wealthfront Advisers
IDXX icon

Wealthfront Advisers’s Idexx Laboratories IDXX Stock Holding History

Wealthfront Advisers’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.86M Sell
13,026
-5,576
-30% -$3.13M 0.01% 383
2026
Q1 		$10.5M Buy
18,602
+1,687
+10% +$1.08M 0.02% 262
2025
Q4 		$11.4M Buy
16,915
+7,438
+78% +$5.07M 0.03% 231
2025
Q3 		$6.05M Buy
9,477
+2,463
+35% +$1.49M 0.01% 349
2025
Q2 		$3.76M Buy
7,014
+468
+7% +$224K 0.01% 434
2025
Q1 		$2.75M Buy
6,546
+428
+7% +$186K 0.01% 459
2024
Q4 		$2.53M Sell
6,118
-1,087
-15% -$477K 0.01% 474
2024
Q3 		$3.64M Sell
7,205
-300
-4% -$146K 0.01% 379
2024
Q2 		$3.66M Sell
7,505
-104
-1% -$52.2K 0.01% 347
2024
Q1 		$4.11M Sell
7,609
-162
-2% -$88.5K 0.01% 315
2023
Q4 		$4.31M Buy
7,771
+1,310
+20% +$615K 0.02% 274
2023
Q3 		$2.83M Sell
6,461
-120
-2% -$59.8K 0.01% 353
2023
Q2 		$3.31M Sell
6,581
-313
-5% -$150K 0.01% 302
2023
Q1 		$3.45M Buy
6,894
+84
+1% +$40.2K 0.02% 276
2022
Q4 		$2.78M Buy
6,810
+2,300
+51% +$893K 0.01% 312
2022
Q3 		$1.47M Buy
4,510
+1,216
+37% +$447K 0.01% 428
2022
Q2 		$1.16M Sell
3,294
-2,312
-41% -$943K 0.01% 469
2022
Q1 		$3.07M Buy
5,606
+1,716
+44% +$903K 0.01% 302
2021
Q4 		$2.56M Sell
3,890
-163
-4% -$102K 0.01% 337
2021
Q3 		$2.52M Buy
4,053
+115
+3% +$77.3K 0.01% 296
2021
Q2 		$2.49M Buy
3,938
+188
+5% +$104K 0.01% 260
2021
Q1 		$1.83M Buy
3,750
+654
+21% +$328K 0.01% 292
2020
Q4 		$1.55M Buy
3,096
+738
+31% +$330K 0.01% 287
2020
Q3 		$927K Buy
2,358
+10
+0.4% +$3.7K 0.01% 339
2020
Q2 		$775K Buy
2,348
+477
+25% +$138K 0.01% 357
2020
Q1 		$453K Sell
1,871
-1,681
-47% -$439K ﹤0.01% 358
2019
Q4 		$928K Buy
3,552
+1,158
+48% +$305K 0.01% 334
2019
Q3 		$651K Buy
2,394
+3
+0.1% +$835 0.01% 351
2019
Q2 		$658K Buy
2,391
+74
+3% +$18.2K 0.01% 350
2019
Q1 		$518K Sell
2,317
-1,527
-40% -$315K ﹤0.01% 364
2018
Q4 		$715K Buy
+3,844
New +$788K 0.01% 303

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wealthfront Advisers's IDXX Position: Q2 2026 in Review

Wealthfront Advisers reduced its Idexx Laboratories (IDXX) stake by 30% in Q2 2026, selling an estimated $3.13M and leaving 13,026 shares worth $6.86M. The position accounts for 0.01% of the portfolio, ranked #383.

Wealthfront Advisers first reported a position in IDXX in Q4 2018 and has held it in 31 quarters since. The position peaked at $11.4M in Q4 2025. 936 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Wealthfront Advisers held 13,026 shares of Idexx Laboratories worth $6.86M as of Q2 2026.
  • Wealthfront Advisers sold 5,576 Idexx Laboratories shares in Q2 2026, an estimated $3.13M.
  • Idexx Laboratories made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #383 holding.
  • Wealthfront Advisers first reported a position in Idexx Laboratories in Q4 2018 and has held it in 31 quarters since.
  • Wealthfront Advisers's Idexx Laboratories position peaked at $11.4M in Q4 2025.
  • 936 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.